

SERTRALINE 25mg Film-coated Tablets

The product strength addresses a therapy gap

- Indicated for the treatment of several mental health conditions:
 - Major Depressive Episodes: It helps manage symptoms during depressive episodes and prevents their recurrence.
 - Panic Disorder: Effective in treating panic attacks, whether with or without agoraphobia.
 - Obsessive-Compulsive Disorder (OCD): Beneficial for adults and pediatric patients aged 6 to 17 years.
 - Social Anxiety Disorder: Helps alleviate symptoms related to social anxiety.
 - Post-Traumatic Stress Disorder (PTSD): Useful in managing PTSD symptoms.

The dossier is available, and the product is already registered in EU countries and the UK

Available strength: 25mg

25mg of sertraline is used as the initial treatment for panic disorders, PTSD, and social anxiety disorder.

 Whether in adults or the pediatric population (ages 6 to 12 years), the recommended starting dose is 25mg of sertraline per day.

Regulatory pathway

• Legal basis: Article 10(1) generic application

Development status

Dossier registered in Europe

Partnership options

- The product is available for out-licensing in select European markets
- The product is also available for licensing outside of Europe

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

Zentiva Group a.s. U Kabelovny529/16, 102 00 Prague 10, Czech Republic



www.Zent2U.com

